News & Events about Cytokinetics Inc.
TipRanks Financial Blog
25days ago
In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK Research Report), with a price t... In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK –...
Cytokinetics, Incorporated (NASDAQ:CYTK Get Rating) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $37.68, for a total value of $471,000.00. Following the completion of the sale, the chief executive officer ...
TipRanks Financial Blog
1month ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocri... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocrine...
Globe Newswire
2 months ago
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and InclusionSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, ...